CT-721 |
Catalog No.GC35753 |
CT-721 es un inhibidor de la quinasa Bcr-Abl potente y dependiente del tiempo con una IC50 de 21,3 nM para la quinasa Bcr-Abl de tipo salvaje y posee actividades contra la leucemia mieloide crÓnica (LMC).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1388710-60-8
Sample solution is provided at 25 µL, 10mM.
CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities[1]. IC50: 21.3 nM (wild-type Bcr-Abl kinase)[1]
[1]. Sun Y, et al. CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia. J Cancer. 2017 Aug 23;8(14):2774-2784.
Average Rating: 5
(Based on Reviews and 25 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *